

## Alpha Fetoprotein Ab-2

### Rabbit Polyclonal Antibody

Cat. #RB-365-A1, or -A (0.5ml, or 1.0ml)

Cat. #RB-365-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)

Cat. #RB-365-PCS (5 Slides) (Positive Control for Histology)

Cat. #RB-365-PCL (0.1ml) (Positive Control for Western Blot)

**Description:** AFP is normally synthesized in the liver, intestinal tract, and yolk sac of the fetus. Antibody to AFP has been shown to be useful in detecting hepatocellular carcinomas (HCC) and germ cell neoplasms, especially yolk sac tumors.

**Comments:** Ab-2 is highly specific to AFP. It is excellent for immunohistochemical staining of formalin-fixed, paraffin-embedded tissues.

**Mol. Wt. of Antigen:** 70kDa

**Epitope:** Not determined

**Species Reactivity:** Human, Pig, and Sheep.  
Does not react with dog. Others-not known.

**Immunogen:** Purified alpha fetoprotein

### Applications and Suggested Dilutions:

- Western Blotting (Ab 1:100 for 2hrs at RT)
- Immunohistology (Formalin/paraffin)  
(Ab 1:100-1:200 for 30 min at RT)
- \* [No special pretreatment is required for the immunohistochemical staining of formalin/paraffin tissues.]

The optimal dilution for a specific application should be determined by the investigator.

**Positive Control:** HEP-G-2 cells. Fetal liver or hepatocellular carcinoma.

**Cellular Localization:** Cytoplasmic

### Supplied As:

Immunoglobulin fraction from rabbit anti-serum. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.

or

Prediluted antibody which is ready-to-use for staining of formalin-fixed, paraffin-embedded tissues.

**Storage and Stability:** Store vial at 4°C. When stored at 2-8°C, this antibody is stable for 24 months.

### Suggested References:

1. Cocquyt V; et al. American Journal of Clinical Oncology, 1996, 19(5):465-8.
2. Morinaga S; et al. Archives of Pathology and Laboratory Medicine, 1996 Jul, 120(7):687-90.

### Limitations and Warranty:

Our products are intended FOR RESEARCH USE ONLY and are not approved for clinical diagnosis, drug use or therapeutic procedures. No products are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our data sheets and website. Our warranty is limited to the actual price paid for the product. NeoMarkers is not liable for any property damage, personal injury, time or effort or economic loss caused by our products.

### Material Safety Data:


This product is not licensed or approved for administration to humans or to animals other than the experimental animals. Standard Laboratory Practices should be followed when handling this material. The chemical, physical, and toxicological properties of this material have not been thoroughly investigated. Appropriate measures should be taken to avoid skin and eye contact, inhalation, and ingestion. The material contains 0.09% sodium azide as a preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material as indicated above. The National Institute of Occupational Safety and Health has issued a bulletin citing the potential explosion hazard due to the reaction of sodium azide with copper, lead, brass, or solder in the plumbing systems. Sodium azide forms hydrazoic acid in acidic conditions and should be discarded in a large volume of running water to avoid deposits forming in metal drainage pipes.

### For Research Use Only

Thermo Fisher Scientific  
Anatomical Pathology  
47777 Warm Springs Blvd.  
Fremont, CA 94539, USA  
Tel: 1-510-991-2800  
Fax: 1-510-991-2826  
<http://www.thermo.com/labvision>



Manufactured by:  
NeoMarkers  
For  
Lab Vision Corporation



Thermo Fisher Scientific  
Anatomical Pathology  
93-96 Chadwick Road, Astmoor  
Runcorn, Cheshire WA7 1PR, UK  
Tel: 44-1928-562600  
Fax: 44-1928-562627  
[Labvision.uk@thermofisher.com](mailto:Labvision.uk@thermofisher.com)

## Alpha Fetoprotein Ab-2

### Rabbit Polyclonal Antibody

Cat. #RB-365-A1, or -A (0.5ml, or 1.0ml )

Cat. #RB-365-R7 (7.0ml) (Ready-to-Use for Immunohistochemical Staining)

Cat. #RB-365-PCS (5 Slides) (Positive Control for Histology)

Cat. #RB-365-PCL (0.1ml) (Positive Control for Western Blot)

#### *Additional Suggested References:*

- Martin de las Mulas J; Gomez-Villamandos JC; Perez J; Mozos E; Estrado M; Mendez A. Immunohistochemical evaluation of canine primary liver carcinomas: distribution of alpha-fetoprotein, carcinoembryonic antigen, keratins and vimentin. *Research in Veterinary Science*, 1995, 59(2):124-7.
- Shinagawa T; Tadokoro M; Maeyama S; Maeda C; Yamaguchi S; Morohoshi T; Ishikawa E. Alpha fetoprotein-producing acinar cell carcinoma of the pancreas showing multiple lines of differentiation. *Virchows Archiv*, 1995, 426(4):419-23.
- Aizawa K; Motoyama T; Suzuki S; Tanaka N; Yabusaki H; Tanaka S; Muto I; Tanaka O; Hatakeyama K. Different characteristics of hepatoid and non-hepatoid alpha-fetoprotein-producing gastric carcinomas: an experimental study using xenografted tumors. *Int Journal of Cancer*, 1994, 58(3):430-5.
- Cummings OW; Ulbright TM; Eble JN; Roth LM. Spermatocytic seminoma: an immunohistochemical study. *Human Pathology*, 1994, 25:54-9.
- Fucich LF; Cheles MK; Thung SN; Gerber MA; Marrogi AJ. Primary vs metastatic hepatic carcinoma. An immunohistochemical study of 34 cases. *Archives of Pathology and Laboratory Medicine*, 1994 Sep, 118(9):927-30.
- Kawamori T; Tanaka T; Kawase Y; Shiroko J; Tanahashi S; Mori H. An alpha-fetoprotein producing pancreatic cystadenocarcinoma. *Clinical Investigator*, 1994 May, 72(5):377-80.
- Kuwashima Y; Uehara T; Kishi K; Shiromizu K; Matsuzawa M; Takayama S. Immunohistochemical characterization of undifferentiated carcinomas of the ovary. *Journal of Cancer Research and Clinical Oncology*, 1994, 120(11):672-7.
- Matsunou H; Konishi F; Jalal RE; Yamamichi N; Mukawa A. Alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. *Cancer*, 1994 Feb 1, 73(3):534-40.
- Terada T; Kida T; Nakanuma Y; Kurumaya H; Doishita K; Takayanagi N. Intrahepatic cholangiocarcinomas associated with nonbiliary cirrhosis. A clinicopathologic study. *Journal of Clinical Gastroenterology*, 1994 Jun, 18(4):335-42.
- Nagai E; Ueyama T; Yao T; Tsuneyoshi M. Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis. *Cancer*, 1993 Sep 15, 72(6):1827-35.
- Okamoto T; Hirabayashi K; Ishiguro T. Immunohistochemical type distinction of alpha-fetoprotein in various alpha-fetoprotein-secreting tumors. *Japanese Journal of Cancer Research*, 1993 Apr, 84(4):360-4.
- Suzuki T; Sasano H; Aoki H; Nagura H; Sasano N; Sano T; Saito M; Watanuki T; Kato H; Aizawa S. Immunohistochemical comparison between anaplastic seminoma and typical seminoma. *Acta Pathologica Japonica*, 1993 Dec, 43(12):751-7.
- Tsuji T; Nagai N. Production of alpha-fetoprotein by human submandibular gland. *International Journal of Developmental Biology*, 1993 Sep, 37(3):497-8.
- Zamecnik M; Patrikova J; Gomolcak P. Yolk sac carcinoma of the stomach with gastrin positivity. *Human Pathology*, 1993 Aug, 24(8):927-8.
- Araki H; Ueda H; Fujimoto S. Immunocytochemical localization of alpha-fetoprotein in the developing and carbon tetrachloride-treated rat liver. *Acta Anatomica*, 1992, 143(3):169-77.
- Chang YC; Nagasue N; Abe S; Taniura H; Kumar DD; Nakamura T. Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. *American Journal of Gastroenterology*, 1992 Mar, 87(3):321-5.

